Summit Therapeutics Inc. or Supernus Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Summit Therapeutics Inc. and Supernus Pharmaceuticals, Inc. have taken different paths in this regard over the past decade.

From 2014 to 2023, Supernus Pharmaceuticals consistently reported higher SG&A expenses, peaking at approximately $377 million in 2022. This represents a staggering 420% increase from their 2014 figures. In contrast, Summit Therapeutics maintained a more conservative approach, with their SG&A expenses growing by about 315% over the same period, reaching around $28 million in 2023.

While Supernus's higher expenses might reflect aggressive market expansion, Summit's strategy suggests a focus on cost efficiency. Investors and stakeholders should consider these trends when evaluating the companies' financial health and strategic priorities.